{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:07:37Z","timestamp":1784657257945,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2501204"],"award-info":[{"award-number":["2021YFC2501204"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071439"],"award-info":[{"award-number":["82071439"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12035-025-04928-z","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:50:18Z","timestamp":1744357818000},"page":"10530-10538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Mendelian randomization study on association of alpha-synuclein and GPNMB with Parkinson\u2019s disease risk and progression"],"prefix":"10.1007","volume":"62","author":[{"given":"Lizhi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yige","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beisha","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"5","key":"4928_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s13205-023-03553-8","volume":"13","author":"H Adam","year":"2023","unstructured":"Adam H, Gopinath SCB, Md Arshad MK, Adam T, Parmin NA, Husein I, Hashim U (2023) An update on pathogenesis and clinical scenario for Parkinson\u2019s disease: diagnosis and treatment. 3 Biotech 13(5):142. https:\/\/doi.org\/10.1007\/s13205-023-03553-8","journal-title":"3 Biotech"},{"issue":"9996","key":"4928_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/s0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386(9996):896\u2013912. https:\/\/doi.org\/10.1016\/s0140-6736(14)61393-3","journal-title":"Lancet"},{"issue":"7","key":"4928_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18(7):435\u2013450. https:\/\/doi.org\/10.1038\/nrn.2017.62","journal-title":"Nat Rev Neurosci"},{"key":"4928_CR4","doi-asserted-by":"publisher","unstructured":"Jan A, Gon\u00e7alves NP, Vaegter CB, Jensen PH, Ferreira N (2021) The prion-like spreading of alpha-synuclein in Parkinson\u2019s disease: update on models and hypotheses. Int J Mol Sci 22 (15). https:\/\/doi.org\/10.3390\/ijms22158338","DOI":"10.3390\/ijms22158338"},{"issue":"Suppl 1","key":"4928_CR5","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","volume":"46","author":"DW Dickson","year":"2018","unstructured":"Dickson DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46(Suppl 1):S30-s33. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.07.033","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"4928_CR6","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/jnc.14809","volume":"150","author":"M Fayyad","year":"2019","unstructured":"Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B, El-Agnaf OMA (2019) Parkinson\u2019s disease biomarkers based on \u03b1-synuclein. J Neurochem 150(5):626\u2013636. https:\/\/doi.org\/10.1111\/jnc.14809","journal-title":"J Neurochem"},{"issue":"6","key":"4928_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K et al (2019) CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol 18(6):573\u2013586. https:\/\/doi.org\/10.1016\/s1474-4422(19)30024-9","journal-title":"Lancet Neurol"},{"key":"4928_CR8","doi-asserted-by":"publisher","unstructured":"Kapsali I, Brinia ME, Constantinides VC (2024) Cerebrospinal fluid total, phosphorylated and oligomeric a-synuclein in Parkinson\u2019s disease: a systematic review, meta-analysis and meta-regression study. Biomedicines 12 (10). https:\/\/doi.org\/10.3390\/biomedicines12102266","DOI":"10.3390\/biomedicines12102266"},{"key":"4928_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.parkreldis.2022.06.001","volume":"99","author":"M Zubelzu","year":"2022","unstructured":"Zubelzu M, Morera-Herreras T, Irastorza G, G\u00f3mez-Esteban JC, Murueta-Goyena A (2022) Plasma and serum alpha-synuclein as a biomarker in Parkinson\u2019s disease: a meta-analysis. Parkinsonism Relat Disord 99:107\u2013115. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.06.001","journal-title":"Parkinsonism Relat Disord"},{"key":"4928_CR10","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3389\/fneur.2019.01388","volume":"10","author":"CW Chang","year":"2019","unstructured":"Chang CW, Yang SY, Yang CC, Chang CW, Wu YR (2019) Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients with Parkinson\u2019s disease. Front Neurol 10:1388. https:\/\/doi.org\/10.3389\/fneur.2019.01388","journal-title":"Front Neurol"},{"issue":"6","key":"4928_CR11","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27(6):954\u2013963. https:\/\/doi.org\/10.1038\/s41591-021-01382-x","journal-title":"Nat Med"},{"key":"4928_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cca.2022.02.006","volume":"529","author":"R Chen","year":"2022","unstructured":"Chen R, Gu X, Wang X (2022) \u03b1-synuclein in Parkinson\u2019s disease and advances in detection. Clin Chim Acta 529:76\u201386. https:\/\/doi.org\/10.1016\/j.cca.2022.02.006","journal-title":"Clin Chim Acta"},{"issue":"47","key":"4928_CR13","doi-asserted-by":"publisher","first-page":"44284","DOI":"10.1074\/jbc.M105343200","volume":"276","author":"VN Uversky","year":"2001","unstructured":"Uversky VN, Li J, Fink AL (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson\u2019s disease and heavy metal exposure. J Biol Chem 276(47):44284\u201344296. https:\/\/doi.org\/10.1074\/jbc.M105343200","journal-title":"J Biol Chem"},{"key":"4928_CR14","doi-asserted-by":"publisher","unstructured":"Diaz-Ortiz ME, Seo Y, Posavi M, Carceles Cordon M, Clark E, Jain N, Charan R, Gallagher MD, et al (2022) GPNMB confers risk for Parkinson\u2019s disease through interaction with \u03b1-synuclein. Science 377 (6608):eabk0637. https:\/\/doi.org\/10.1126\/science.abk0637","DOI":"10.1126\/science.abk0637"},{"issue":"6","key":"4928_CR15","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.1007\/s12035-017-0707-z","volume":"55","author":"KM Budge","year":"2018","unstructured":"Budge KM, Neal ML, Richardson JR, Safadi FF (2018) Glycoprotein NMB: an emerging role in neurodegenerative disease. Mol Neurobiol 55(6):5167\u20135176. https:\/\/doi.org\/10.1007\/s12035-017-0707-z","journal-title":"Mol Neurobiol"},{"issue":"6","key":"4928_CR16","doi-asserted-by":"publisher","first-page":"1708.e1707","DOI":"10.1016\/j.neurobiolaging.2012.10.019","volume":"34","author":"L Pihlstr\u00f8m","year":"2013","unstructured":"Pihlstr\u00f8m L, Axelsson G, Bj\u00f8rnar\u00e5 KA, Dizdar N, Fardell C, Forsgren L, Holmberg B, Larsen JP et al (2013) Supportive evidence for 11 loci from genome-wide association studies in Parkinson\u2019s disease. Neurobiol Aging 34(6):1708.e1707-1713. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2012.10.019","journal-title":"Neurobiol Aging"},{"key":"4928_CR17","doi-asserted-by":"publisher","unstructured":"Santiago JA, Quinn JP, Potashkin JA (2023) Co-expression network analysis identifies molecular determinants of loneliness associated with neuropsychiatric and neurodegenerative diseases. Int J Mol Sci 24 (6). https:\/\/doi.org\/10.3390\/ijms24065909","DOI":"10.3390\/ijms24065909"},{"issue":"10","key":"4928_CR18","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","volume":"49","author":"D Chang","year":"2017","unstructured":"Chang D, Nalls MA, Hallgr\u00edmsd\u00f3ttir IB, Hunkapiller J, van der Brug M, Cai F, Kerchner GA, Ayalon G et al (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci. Nat Genet 49(10):1511\u20131516. https:\/\/doi.org\/10.1038\/ng.3955","journal-title":"Nat Genet"},{"issue":"1","key":"4928_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12974-018-1100-1","volume":"15","author":"ML Neal","year":"2018","unstructured":"Neal ML, Boyle AM, Budge KM, Safadi FF, Richardson JR (2018) The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor. J Neuroinflammation 15(1):73. https:\/\/doi.org\/10.1186\/s12974-018-1100-1","journal-title":"J Neuroinflammation"},{"key":"4928_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2018.08.013","volume":"120","author":"EB Moloney","year":"2018","unstructured":"Moloney EB, Moskites A, Ferrari EJ, Isacson O, Hallett PJ (2018) The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson\u2019s disease patients and increases after lysosomal stress. Neurobiol Dis 120:1\u201311. https:\/\/doi.org\/10.1016\/j.nbd.2018.08.013","journal-title":"Neurobiol Dis"},{"issue":"7","key":"4928_CR21","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1007\/s12035-020-01921-6","volume":"57","author":"KM Budge","year":"2020","unstructured":"Budge KM, Neal ML, Richardson JR, Safadi FF (2020) Transgenic overexpression of GPNMB protects against MPTP-induced neurodegeneration. Mol Neurobiol 57(7):2920\u20132933. https:\/\/doi.org\/10.1007\/s12035-020-01921-6","journal-title":"Mol Neurobiol"},{"issue":"1","key":"4928_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41467-021-27387-1","volume":"12","author":"G Png","year":"2021","unstructured":"Png G, Barysenka A, Repetto L, Navarro P, Shen X, Pietzner M, Wheeler E, Wareham NJ et al (2021) Mapping the serum proteome to neurological diseases using whole genome sequencing. Nat Commun 12(1):7. https:\/\/doi.org\/10.1038\/s41467-021-27387-1","journal-title":"Nat Commun"},{"key":"4928_CR23","doi-asserted-by":"publisher","first-page":"106001","DOI":"10.1016\/j.parkreldis.2024.106001","volume":"120","author":"K Li","year":"2024","unstructured":"Li K, Wang P, Li W, Yan JH, Ge YL, Zhang JR, Wang F, Mao CJ et al (2024) The association between plasma GPNMB and Parkinson\u2019s disease and multiple system atrophy. Parkinsonism Relat Disord 120:106001. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106001","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"4928_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s12031-019-01411-y","volume":"69","author":"S Zhu","year":"2019","unstructured":"Zhu S, Wuolikainen A, Wu J, \u00d6hman A, Wingsle G, Moritz T, Andersen PM, Forsgren L et al (2019) Targeted multiple reaction monitoring analysis of CSF identifies UCHL1 and GPNMB as candidate biomarkers for ALS. J Mol Neurosci 69(4):643\u2013657. https:\/\/doi.org\/10.1007\/s12031-019-01411-y","journal-title":"J Mol Neurosci"},{"issue":"19","key":"4928_CR25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin CA, Khera AV, Kathiresan S (2017) Mendelian randomization. JAMA 318(19):1925\u20131926. https:\/\/doi.org\/10.1001\/jama.2017.17219","journal-title":"JAMA"},{"issue":"9","key":"4928_CR26","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/s41593-021-00886-6","volume":"24","author":"C Yang","year":"2021","unstructured":"Yang C, Farias FHG, Ibanez L, Suhy A, Sadler B, Fernandez MV, Wang F, Bradley JL et al (2021) Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nat Neurosci 24(9):1302\u20131312. https:\/\/doi.org\/10.1038\/s41593-021-00886-6","journal-title":"Nat Neurosci"},{"issue":"12","key":"4928_CR27","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","volume":"53","author":"E Ferkingstad","year":"2021","unstructured":"Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, Gunnarsdottir K, Helgason A et al (2021) Large-scale integration of the plasma proteome with genetics and disease. Nat Genet 53(12):1712\u20131721. https:\/\/doi.org\/10.1038\/s41588-021-00978-w","journal-title":"Nat Genet"},{"issue":"7708","key":"4928_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-018-0175-2","volume":"558","author":"BB Sun","year":"2018","unstructured":"Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T et al (2018) Genomic atlas of the human plasma proteome. Nature 558(7708):73\u201379. https:\/\/doi.org\/10.1038\/s41586-018-0175-2","journal-title":"Nature"},{"issue":"12","key":"4928_CR29","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/s1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA et al (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 18(12):1091\u20131102. https:\/\/doi.org\/10.1016\/s1474-4422(19)30320-5","journal-title":"Lancet Neurol"},{"issue":"7944","key":"4928_CR30","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki MI, Karjalainen J, Palta P, Sipil\u00e4 TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H et al (2023) FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613(7944):508\u2013518. https:\/\/doi.org\/10.1038\/s41586-022-05473-8","journal-title":"Nature"},{"issue":"6","key":"4928_CR31","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/mds.27659","volume":"34","author":"C Blauwendraat","year":"2019","unstructured":"Blauwendraat C, Heilbron K, Vallerga CL, Bandres-Ciga S, von Coelln R, Pihlstr\u00f8m L, Sim\u00f3n-S\u00e1nchez J, Schulte C et al (2019) Parkinson\u2019s disease age at onset genome-wide association study: defining heritability, genetic loci, and \u03b1-synuclein mechanisms. Mov Disord 34(6):866\u2013875. https:\/\/doi.org\/10.1002\/mds.27659","journal-title":"Mov Disord"},{"issue":"12","key":"4928_CR32","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/mds.27845","volume":"34","author":"H Iwaki","year":"2019","unstructured":"Iwaki H, Blauwendraat C, Leonard HL, Kim JJ, Liu G, Maple-Gr\u00f8dem J, Corvol JC, Pihlstr\u00f8m L et al (2019) Genomewide association study of Parkinson\u2019s disease clinical biomarkers in 12 longitudinal patients\u2019 cohorts. Mov Disord 34(12):1839\u20131850. https:\/\/doi.org\/10.1002\/mds.27845","journal-title":"Mov Disord"},{"issue":"1","key":"4928_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41588-021-00968-y","volume":"54","author":"X Liu","year":"2022","unstructured":"Liu X, Tong X, Zou Y, Lin X, Zhao H, Tian L, Jie Z, Wang Q et al (2022) Mendelian randomization analyses support causal relationships between blood metabolites and the gut microbiome. Nat Genet 54(1):52\u201361. https:\/\/doi.org\/10.1038\/s41588-021-00968-y","journal-title":"Nat Genet"},{"issue":"5","key":"4928_CR34","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1017\/s0033291716003172","volume":"47","author":"SH Gage","year":"2017","unstructured":"Gage SH, Jones HJ, Burgess S, Bowden J, Davey Smith G, Zammit S, Munaf\u00f2 MR (2017) Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychol Med 47(5):971\u2013980. https:\/\/doi.org\/10.1017\/s0033291716003172","journal-title":"Psychol Med"},{"issue":"4","key":"4928_CR35","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41588-019-0350-x","volume":"51","author":"S Sanna","year":"2019","unstructured":"Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, V\u00f5sa U, Mujagic Z, Masclee AAM et al (2019) Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet 51(4):600\u2013605. https:\/\/doi.org\/10.1038\/s41588-019-0350-x","journal-title":"Nat Genet"},{"issue":"3","key":"4928_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (2023) Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14(3):176. https:\/\/doi.org\/10.1038\/s41419-023-05672-9","journal-title":"Cell Death Dis"},{"key":"4928_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","volume":"18","author":"H Ye","year":"2023","unstructured":"Ye H, Robak LA, Yu M, Cykowski M, Shulman JM (2023) Genetics and pathogenesis of Parkinson\u2019s syndrome. Annu Rev Pathol 18:95\u2013121. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-031521-034145","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"4928_CR38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/jpd-202472","volume":"11","author":"TA Mestre","year":"2021","unstructured":"Mestre TA, Fereshtehnejad SM, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ, Halliday G et al (2021) Parkinson\u2019s disease subtypes: critical appraisal and recommendations. J Parkinsons Dis 11(2):395\u2013404. https:\/\/doi.org\/10.3233\/jpd-202472","journal-title":"J Parkinsons Dis"},{"key":"4928_CR39","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.biopha.2018.05.026","volume":"104","author":"A Khodadadian","year":"2018","unstructured":"Khodadadian A, Hemmati-Dinarvand M, Kalantary-Charvadeh A, Ghobadi A, Mazaheri M (2018) Candidate biomarkers for Parkinson\u2019s disease. Biomed Pharmacother 104:699\u2013704. https:\/\/doi.org\/10.1016\/j.biopha.2018.05.026","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4928_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/mds.27492","volume":"34","author":"B Mollenhauer","year":"2019","unstructured":"Mollenhauer B, Zimmermann J, Sixel-Doering F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E et al (2019) Baseline predictors for progression 4 years after Parkinson\u2019s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov Dis 34(1):67\u201377. https:\/\/doi.org\/10.1002\/mds.27492","journal-title":"Mov Dis"},{"issue":"1","key":"4928_CR41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-023-00622-7","volume":"18","author":"T Koeglsperger","year":"2023","unstructured":"Koeglsperger T, Rumpf SL, Schlie\u00dfer P, Struebing FL, Brendel M, Levin J, Trenkwalder C, H\u00f6glinger GU et al (2023) Neuropathology of incidental Lewy body & prodromal Parkinson\u2019s disease. Mol Neurodegener 18(1):32. https:\/\/doi.org\/10.1186\/s13024-023-00622-7","journal-title":"Mol Neurodegener"},{"issue":"2","key":"4928_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Tredici KD, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24(2):197\u2013211. https:\/\/doi.org\/10.1016\/S0197-4580(02)00065-9","journal-title":"Neurobiol Aging"},{"issue":"Suppl 1","key":"4928_CR43","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/s1353-8020(11)70011-6","volume":"18","author":"WD van de Berg","year":"2012","unstructured":"van de Berg WD, Hepp DH, Dijkstra AA, Rozemuller JA, Berendse HW, Foncke E (2012) Patterns of \u03b1-synuclein pathology in incidental cases and clinical subtypes of Parkinson\u2019s disease. Parkinsonism Relat Disord 18(Suppl 1):S28-30. https:\/\/doi.org\/10.1016\/s1353-8020(11)70011-6","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"4928_CR44","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1007\/s12035-023-03206-0","volume":"60","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Lin Z, He Y, Jiang J, Hu D (2023) Mendelian randomization analysis reveals no causal relationship between plasma \u03b1-synuclein and Parkinson\u2019s disease. Mol Neurobiol 60(4):2268\u20132276. https:\/\/doi.org\/10.1007\/s12035-023-03206-0","journal-title":"Mol Neurobiol"},{"issue":"1","key":"4928_CR45","doi-asserted-by":"publisher","first-page":"e53250","DOI":"10.1371\/journal.pone.0053250","volume":"8","author":"M Wennstr\u00f6m","year":"2013","unstructured":"Wennstr\u00f6m M, Surova Y, Hall S, Nilsson C, Minthon L, Bostr\u00f6m F, Hansson O, Nielsen HM (2013) Low CSF levels of both \u03b1-synuclein and the \u03b1-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 8(1):e53250. https:\/\/doi.org\/10.1371\/journal.pone.0053250","journal-title":"PLoS One"},{"issue":"3","key":"4928_CR46","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/ene.12176","volume":"21","author":"KD van Dijk","year":"2014","unstructured":"van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, van de Berg WD (2014) Reduced \u03b1-synuclein levels in cerebrospinal fluid in Parkinson\u2019s disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol 21(3):388\u2013394. https:\/\/doi.org\/10.1111\/ene.12176","journal-title":"Eur J Neurol"},{"issue":"1","key":"4928_CR47","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.024","volume":"349","author":"T Tokuda","year":"2006","unstructured":"Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG et al (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson\u2019s disease. Biochem Biophys Res Commun 349(1):162\u2013166. https:\/\/doi.org\/10.1016\/j.bbrc.2006.08.024","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"4928_CR48","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jamaneurol.2013.3861","volume":"70","author":"JH Kang","year":"2013","unstructured":"Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Walig\u00f3rska T, Taylor P et al (2013) Association of cerebrospinal fluid \u03b2-amyloid 1\u201342, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10):1277\u20131287. https:\/\/doi.org\/10.1001\/jamaneurol.2013.3861","journal-title":"JAMA Neurol"},{"issue":"1","key":"4928_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40035-024-00449-2","volume":"13","author":"Y Kuang","year":"2024","unstructured":"Kuang Y, Mao H, Huang X, Chen M, Dai W, Gan T, Wang J, Sun H et al (2024) \u03b1-Synuclein seeding amplification assays for diagnosing synucleinopathies: an innovative tool in clinical implementation. Transl Neurodegener 13(1):56. https:\/\/doi.org\/10.1186\/s40035-024-00449-2","journal-title":"Transl Neurodegener"},{"issue":"10","key":"4928_CR50","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1002\/mds.29566","volume":"38","author":"L Wan","year":"2023","unstructured":"Wan L, Fu Y, Chen Z, Long Z, Chen D, Yuan X, Zhu S, Peng L et al (2023) No correlation between plasma GPNMB levels and multiple system atrophy in Chinese cohorts. Mov Disord 38(10):1956\u20131961. https:\/\/doi.org\/10.1002\/mds.29566","journal-title":"Mov Disord"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-04928-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-04928-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-04928-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T08:47:17Z","timestamp":1753346837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-04928-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["4928"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-04928-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4525984\/v1","asserted-by":"object"}]},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is a Mendelian randomization study, whose data were from public GWAS. Therefore, all relevant ethics statements are shown in the original GWAS, and the study did not approve an ethical statement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}